Archemin

Advice & reporting for the chemical and pharmaceutical industries

Dexdor reimbursed in Belgium (Class I reimbursement)

Wed, 25/07/2012 - 7:56am -- Inneke Van de Vijver

As from 1 August 2012 on Dexdor, a novel sedative with unique properties compared to current standard sedatives is reimbursed for hospitalised patients under Chapter I in Belgium.

Dexdor (dexmedetomidine) is indicated for sedation of adult ICU patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Dexdor addresses the unmet needs in Intensive Care Unit (ICU) sedation by improving the quality of sedation and the patient management.

Clinical studies established that compared to moderate ICU sedation dexmedetomidine

  • maintains the targeted sedation level which is as effective as standard care, but simultaneously improves the quality of sedation, making patients more easily arousable, more co-operative and better able to communicate
  • decreases the length of invasive mechanical ventilation and ICU stay
  • has analgesic properties
  • reduces the incidence of delirium and improves cognitive function
  • may provide sedation that is close to natural NREM sleep
  • is generally well tolerated